Redeye provides an update following the Q4 report. Sales increased for the full year by 5% YoY, with a EBITDA margin of 9%. In Q4, sales came in lower than our estimate and we reduce the growth rate somewhat for the full year to 19% (21%) with a EBITDA margin of 9% (15%).

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases